0001438133-26-000010
SEC filingRevenue grew 7.9% to $1.01B, driven by pump volume and ASP, while gross margin expanded 200 bps to 54%.
Tandem Diabetes Care, Inc. describes itself as a global leader in insulin delivery and diabetes technology. The company designs, develops, and commercializes advanced solutions that reduce the burden of diabetes management. It serves nearly 500,000 people living with diabetes in more than 25 countries. The addressable market includes people with type 1 diabetes and, since 2025, people with type 2 diabetes requiring intensive insulin therapy. The company estimates about 5 million people with type 1 diabetes globally (2 million in the U.S.) and about 2.5 million people in the U.S. with type 2 diabetes requiring intensive insulin therapy.
The filing does not explicitly define formal reporting segments for the Business section. The company operates as a single segment focused on insulin pump systems and related supplies. This includes durable insulin pumps (t:slim X2 and Tandem Mobi) and single-use supplies (cartridges and infusion sets). Revenue share by segment is not disclosed.
Tandem's key pump platforms are the t:slim X2 (launched 2016) and the Tandem Mobi (launched 2024). Both feature Control-IQ+ hybrid closed-loop technology, which is the third-generation algorithm launched in 2025. Control-IQ+ is indicated for type 1 diabetes ages 2+ and for type 2 diabetes ages 18+ in the U.S. The pumps integrate with multiple CGM sensors including Dexcom G6, G7, and Abbott FreeStyle Libre 2 Plus and 3 Plus. Additionally, the company offers the Tandem Device Updater (PC/Mac tool for software updates), Tandem Source (web-based data management platform), and Sugarmate (mobile app for diabetes data visualization).
In the United States and Canada, Tandem employs direct sales, customer support, and clinical teams, partnering with independent distributors for order fulfillment. Internationally, the company historically contracted with distributors who handled sales, support, and fulfillment. In 2026, Tandem began transitioning to direct operations in the United Kingdom, Austria, and Switzerland, with plans to continue in additional markets. For the year ended December 31, 2025, two independent distributors each accounted for more than 10% of worldwide sales, indicating customer concentration.
The medical device industry for insulin delivery is intensely competitive. Tandem explicitly names Beta Bionics, Insulet, Medtronic, mylife (formerly Ypsomed), and Sequel as competitors. The company faces competition from new entrants developing insulin delivery systems and related software applications, as well as from companies pursuing alternative therapies.
Tandem's strategy is to redefine global leadership in insulin delivery through commercial excellence, patient-first reimbursement choices, and a differentiated device portfolio. Key strategic pillars include offering flexibility and choice across intelligent insulin delivery systems, pursuing a multi-channel coverage and reimbursement strategy in the U.S. (both durable medical equipment and pharmacy channels), and driving innovation in pump platforms. The pipeline includes an extended-wear infusion site for Mobi (transforming it into a tubeless patch), a next-generation patch pump leveraging Sigi technology, extended-wear infusion set technology, dual glucose-ketone sensor integration, and algorithm advancement toward fully closed loop technology.
As of December 31, 2025, Tandem had approximately 2,500 regular full-time employees, primarily in the United States, Canada, and Europe. The company emphasizes culture, diversity, and inclusion. It offers comprehensive training programs (Emerging Leaders, Leading in Tandem) with over 94% retention and 14% promotion rate for participants. Compensation is designed to attract and retain talent, including equity awards and an employee stock purchase program. Employee health and safety is prioritized through wellness programs and safety training.
For the year ended December 31, 2025, Tandem Diabetes Care reported total sales of $1.01 billion, a 7.9% increase from $940.2 million in 2024. The growth was driven by higher pump volumes (over 126,000 pumps shipped worldwide vs. over 120,000 in 2024) and improved average selling prices. U.S. sales rose 5.1% to $706.9 million, while international sales grew 15.0% to $307.8 million, benefiting from favorable foreign currency exchange rates. Gross profit increased 11.5% to $546.0 million, and gross margin expanded 200 basis points to 54%, primarily due to higher ASPs and reduced non-manufacturing costs. The prior year margin benefited by approximately one percentage point from the Tandem Choice program, which had no comparable impact in 2025.
Operating loss widened significantly to $187.3 million from $99.1 million, largely due to $75.2 million in acquired in-process R&D expenses (related to the revised AMF purchase agreement) and $20.0 million in litigation and settlement expenses (Roche Cross-License Agreement). SG&A expenses rose to $445.0 million, including $6.7 million in non-recurring facility impairment costs and $4.2 million in restructuring costs, while R&D expenses decreased slightly to $193.1 million. Net loss was $204.7 million, compared to $96.0 million in 2024.
In the United States, pump sales increased to $353.9 million (up 7.7% YoY), and supplies and other revenue grew to $353.1 million (up 12.5% YoY). The Tandem Choice program contributed $30.2 million in 2024 but had no impact in 2025. Pump shipments in the U.S. exceeded 86,000 units, up from nearly 81,000. Internationally, pump sales rose to $110.3 million (up 4.5% YoY), and supplies and other revenue increased to $197.5 million (up 22.0% YoY), driven by volume growth and favorable FX. The company is expanding its addressable market to include type 2 diabetes patients requiring intensive insulin therapy.
Management highlighted a strategic shift toward a multi-channel managed care strategy, including pharmacy benefit reimbursement. In 2026, the company plans to transition to a "pay-as-you-go" model, which will eliminate upfront pump reimbursement and distribute revenue across ongoing supply purchases. This is expected to initially decrease pump-related sales and gross profit but increase recurring supply revenue over the four-year customer lifecycle. The company also noted that seasonality related to insurance deductibles may diminish under this model. Key pipeline developments include a tubeless, extended-wear infusion site for Mobi, a next-generation patch pump (Sigi technology), extended-wear infusion sets, dual glucose-ketone sensor integration, and fully closed-loop algorithm advancements. Regulatory milestones include CE Mark approval for Mobi with Control-IQ+ in May 2025 and Android availability in the U.S. in December 2025.
As of December 31, 2025, Tandem held $90.6M in cash and equivalents plus $202.0M in short-term investments, totaling $292.6M in liquid assets. Total debt stood at $314.9M, primarily composed of $310.0M net carrying amount of 1.50% Convertible Senior Notes due 2029 and a $4.9M promissory note. Shareholders' equity was $155.2M, reflecting accumulated deficit of $1.25B offset by additional paid-in capital of $1.40B. Inventory was $128.8M, down 14% from $149.6M in 2024. Deferred revenue (current and long-term) totaled $18.0M, mainly from pump warranty and software update obligations.
The company reported $365.4M in purchase commitments as of year-end, primarily for raw materials and finished goods. Timing breakdown: $267.7M due within one year and $97.7M due in the subsequent year. Additionally, operating lease liabilities totaled $134.4M (present value), with weighted-average remaining term of 8.6 years. The warranty reserve was $55.3M, up from $51.4M in 2024.
Tandem did not repurchase shares in 2025, but in 2024 it repurchased 1.1M shares for $30.0M. No dividends were paid. Debt activity in 2025 included the maturity of $40.8M of 2025 Notes, leaving only the 2029 Notes ($316.3M principal) outstanding. Capital expenditures were $19.9M (2.0% of sales), primarily for manufacturing equipment. The company also paid $78.6M for acquired IPR&D (AMF Medical revised terms).
Tandem operates as a single reportable segment: Insulin Pumps and Supplies. Sales in 2025 were $1,014.7M, of which 69.6% came from the United States ($706.9M) and 30.4% from international markets ($307.8M). International sales grew 15.0% YoY, while US sales grew 5.1%. The company sells through distributors (63% of US sales) and directly. Product mix: Pump sales $464.1M, Supplies and other $550.6M; no Tandem Choice deferred revenue in 2025 (program ended 2024).
Tandem Diabetes Care continues to face significant financial challenges, with an accumulated deficit of $1.3 billion and net losses in each of the last three fiscal years. The company's ability to achieve sustained profitability depends on increasing product sales, managing costs, and successfully executing its multi-channel managed care strategy, which includes a shift to a pharmacy benefit model that eliminates upfront pump reimbursement. This transition could cause near-term declines in sales and gross profit.
The insulin pump market is intensely competitive, with major players including Beta Bionics, Insulet, Medtronic, mylife, and Sequel. Tandem's near-total reliance on sales of insulin pumps and related supplies makes it vulnerable to competitive pricing, new product introductions, and technological breakthroughs such as GLP-1 drugs, which have already negatively impacted the insulin therapy market. Customer retention is critical due to recurring supply sales.
A key development is the CMS final rule in December 2025 introducing a competitive bidding process and monthly rental payment model for insulin pumps, which could reduce reimbursement rates and alter revenue recognition timing. The company also faces ongoing regulatory scrutiny from the FDA and Notified Bodies, with potential for product recalls, warning letters, or suspension of clearances. Compliance with U.S. federal and state fraud and abuse laws, as well as international anti-bribery laws, remains a significant compliance burden.
Tandem depends on a limited number of third-party suppliers, including international sources in China, Mexico, and Costa Rica. Tariffs, trade disputes, and supply disruptions could impair manufacturing. The company is also scaling manufacturing and outsourcing cartridge production, which introduces execution risk. Any disruption at its primary facilities in San Diego could severely impact operations.
The company processes sensitive health data and is subject to stringent U.S. and international privacy laws (e.g., HIPAA, GDPR, CCPA). Cybersecurity threats, including ransomware and supply chain attacks, pose risks to product safety and business continuity. Past recalls, such as the March 2024 t:connect mobile app recall, highlight vulnerabilities in connected devices.
Tandem has $316.3 million in convertible notes due 2029, requiring significant cash for interest and potential repurchase upon a fundamental change. The capped call transactions may mitigate dilution but introduce counterparty risk. Future capital needs may require additional debt or equity financing, diluting existing stockholders.
International sales (~30% of total) expose Tandem to foreign currency fluctuations, trade barriers, and political instability. Inflation and economic uncertainty could affect consumer demand and increase costs. The company has begun hedging currency exposure but faces ongoing volatility.
The provided excerpt from the 10-K filing includes the auditor's report, balance sheets, and income statement, but does not contain the consolidated statements of cash flows. Therefore, no cash flow analysis can be performed. The analysis relies on explicitly stated figures from the cash flow statement, which are absent.